Lineage Cell Therapeutics vs uniQure
uniQure reported revenue of $16 million in fiscal 2025, about the same as Lineage Cell Therapeutics' $15 million in fiscal 2025. Lineage Cell Therapeutics' revenue grew 53.2% in its latest year, and uniQure's fell 40.6%. Lineage Cell Therapeutics had an operating margin of -251.6%, against -1151.4% at uniQure. Free cash flow was −$19 million at Lineage Cell Therapeutics and −$178 million at uniQure.
Side by side
| Lineage Cell Therapeutics | uniQure | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $15M | $16M |
| Revenue growth | 53.2% | −40.6% |
| Revenue growth a year, last 5 years | 52.0% | −15.6% |
| Gross margin | — | 89.5% |
| Operating margin | −251.6% | −1,151.4% |
| Net margin | −436.5% | −1,236.0% |
| Free cash flow | −$19M | −$178M |
| Free cash flow margin | −133.6% | −1,108.2% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 14.9% | 18.2% |
| Last close | $0.82 | $20.23 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $878,348, sold $0 | sold $19.8 million |
| Piotroski F-score | — | 2 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Lineage Cell TherapeuticsuniQure
Operating margin
Percent of revenue
Lineage Cell TherapeuticsuniQure
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Lineage Cell TherapeuticsuniQure
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Lineage Cell Therapeutics and uniQure pages.